IAM
NVCT icon

Iridian Asset Management’s Nuvectis Pharma NVCT Stock Holding History

Iridian Asset Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.3M Buy
777,078
+125,321
+19% +$1.4M 4.91% 8
2026
Q1 		$5.04M Buy
651,757
+65,437
+11% +$561K 2.04% 16
2025
Q4 		$4.43M Buy
586,320
+180,699
+45% +$1.18M 1.63% 23
2025
Q3 		$2.44M Buy
405,621
+32,904
+9% +$226K 0.96% 30
2025
Q2 		$2.78M Buy
372,717
+118,745
+47% +$1.08M 0.96% 29
2025
Q1 		$2.48M Buy
+253,972
New +$1.83M 0.78% 31
2024
Q4 		– Sell
-55,380
Closed -$348K – 53
2024
Q3 		$348K Buy
+55,380
New +$364K 0.07% 48

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Iridian Asset Management's NVCT Position: Q2 2026 in Review

Iridian Asset Management increased its Nuvectis Pharma (NVCT) stake by 19% in Q2 2026, buying an estimated $1.4M and bringing the position to 777,078 shares worth $14.3M. The position accounts for 4.91% of the portfolio, ranked #8.

Iridian Asset Management first reported a position in NVCT in Q3 2024 and has held it in 7 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Iridian Asset Management held 777,078 shares of Nuvectis Pharma worth $14.3M as of Q2 2026.
  • Iridian Asset Management bought 125,321 Nuvectis Pharma shares in Q2 2026, an estimated $1.4M.
  • Nuvectis Pharma made up 4.91% of Iridian Asset Management's portfolio in Q2 2026, its #8 holding.
  • Iridian Asset Management first reported a position in Nuvectis Pharma in Q3 2024 and has held it in 7 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.